Gentle reminder of ANP links to Sarepta….hope we follow Sarepta's price trajectory... $60m to $800m market cap increase after Phase 2
Our team has intimate knowledge of the Eteplirsen weaknesses and potential synergies with ATL1102.
QUALITY....ATL1102 for DMD –Scientific Advisory Board
Dr. Ian Woodcock MD (Principal-Investigator) Royal Childrens Hospital (RCH) Neuromuscular Fellow, Melbourne Australia Professor Monique Ryan MD (Co- Investigator) Director Neurology Department, Head of Royal Children’s Hospital, Neuromuscular Clinic RCH, MCRI, Melbourne Australia Professor
Steve Wilton Ph.D Western Australian Neuroscience Research Institute (NRI), Foundation Chair in Molecular Therapy at Murdoch University, Perth, Western Australia: Patent holder on target sequence of Sarepta’s drug eteplirsen and all additional exon-skipping (Splice Switching Oligimer) drugs
Professor Sue Fletcher, PhD Principal Research Fellow, NRI Murdoch University, Perth, Western Australia: Patent holder on target sequence of Sarepta’s drug eteplirsen and all additional exon-skipping drugs
Dr. Gillian Butler-Browne, PhD Director, Centre of Research in Myology, Sorbonne Universités, INSERM, Paris, France: Expert in inflammatory muscle disease
Mr William Goolsbee (SAB Chairman) Antisense Therapeutics Ltd, non-executive director: Chairman, Sarepta Therapeutics, 2010-2014, Developers of eteplirsen for the treatment of DMD
Gentle reminder of ANP links to Sarepta….hope we follow...
-
- There are more pages in this discussion • 174 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
